Stockreport

Cyclerion Updates Corporate Progress

Cyclerion Therapeutics, Inc.  (CYCN) 
PDF – Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –       – Closed enrollment for IW-6463 tra [Read more]